8P The characterization of tumors associated with the antitumor activity of lenvatinib plus anti-PD-1 antibody combination therapy in a mouse syngeneic model panel

Abstract

Lenvatinib is a multiple receptor tyrosine kinase inhibitor targeting mainly vascular endothelial growth factor and fibroblast growth factor receptors. We also reported that lenvatinib has immunomodulatory activity that contributes to the antitumor activity of lenvatinib and enhances the antitumor activity in combination treatment with anti-PD-1 antibody (anti-PD-1). In this study, we investigated the characters of tumors associated with the antitumor activity of the lenvatinib plus anti-PD-1 combination treatment.